Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vafidemstat - Oryzon Genomics

Drug Profile

Vafidemstat - Oryzon Genomics

Alternative Names: ORY-2001

Latest Information Update: 31 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oryzon
  • Class Antidementias; Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Lysine specific demethylase 1 inhibitors; Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Aggression; Alzheimer's disease; Multiple sclerosis
  • No development reported Dementia; Parkinson's disease

Most Recent Events

  • 22 Oct 2019 Oryzon Genomics completes the phase IIa REIMAGINE trial in Aggression in Spain (EudraCT2018-002140-88)
  • 03 Oct 2019 Efficacy and adverse events data from the phase IIb REIMAGINE trial in Aggression (attention deficit hyperactivity disorder, autistic spectrum disorder and borderline personality disorder cohort) released by Oryzon Genomics
  • 03 Oct 2019 Oryzon Genomics plans the phase IIb COLONNADE trial in Autistic spectrum disorder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top